[go: up one dir, main page]

PL2714071T3 - Zindywidualizowane szczepionki przeciwrakowe - Google Patents

Zindywidualizowane szczepionki przeciwrakowe

Info

Publication number
PL2714071T3
PL2714071T3 PL12723117T PL12723117T PL2714071T3 PL 2714071 T3 PL2714071 T3 PL 2714071T3 PL 12723117 T PL12723117 T PL 12723117T PL 12723117 T PL12723117 T PL 12723117T PL 2714071 T3 PL2714071 T3 PL 2714071T3
Authority
PL
Poland
Prior art keywords
cancer
individualized vaccines
individualized
vaccines
Prior art date
Application number
PL12723117T
Other languages
English (en)
Inventor
Ugur Sahin
Sebastian Kreiter
Mustafa DIKEN
Jan DIEKMANN
Michael Koslowski
Cedrik Britten
John Castle
Martin LÖWER
Bernhard RENARD
Tana Omokoko
Johannes Hendrikus DE GRAAF
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50185364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2714071(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Priority claimed from PCT/EP2012/002209 external-priority patent/WO2012159754A2/en
Publication of PL2714071T3 publication Critical patent/PL2714071T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40Population genetics; Linkage disequilibrium
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Mycology (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
PL12723117T 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwrakowe PL2714071T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP12723117.3A EP2714071B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
PL2714071T3 true PL2714071T3 (pl) 2019-12-31

Family

ID=50185364

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18199105T PL3473267T3 (pl) 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwnowotworowe
PL12723117T PL2714071T3 (pl) 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwrakowe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18199105T PL3473267T3 (pl) 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwnowotworowe

Country Status (9)

Country Link
EP (4) EP2714071B1 (pl)
CY (3) CY1122110T1 (pl)
DK (1) DK3473267T3 (pl)
HR (1) HRP20191535T1 (pl)
ME (1) ME03498B (pl)
PL (2) PL3473267T3 (pl)
RS (1) RS59369B1 (pl)
SI (1) SI2714071T1 (pl)
SM (1) SMT201900521T1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911616QA (en) 2011-05-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
EP2714071B1 (en) 2011-05-24 2019-07-10 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
IL258688B2 (en) * 2015-10-12 2023-04-01 Nantomics Llc Compositions and methods for cancer viral neoepitopes
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7477888B2 (ja) * 2018-11-15 2024-05-02 ノイスコム アーゲー 個別化された癌ワクチンの作製のための癌変異の選択
AU2022245391A1 (en) * 2021-03-26 2023-10-12 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU1774299A (en) 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
ES2330078T3 (es) * 1999-09-16 2009-12-04 Eisai Corporation Of North America Acidos nucleicos que codifican polipeptidos poliepitope.
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
US20060204523A1 (en) * 2001-11-26 2006-09-14 Khromykh Alexander A Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
KR102017898B1 (ko) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
EP2714071B1 (en) 2011-05-24 2019-07-10 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer

Also Published As

Publication number Publication date
EP3473267A1 (en) 2019-04-24
SI2714071T1 (sl) 2019-11-29
ME03498B (me) 2020-04-20
EP2714071A2 (en) 2014-04-09
EP4223311A1 (en) 2023-08-09
EP3473267B1 (en) 2021-09-08
SMT201900521T1 (it) 2019-11-13
DK3473267T3 (da) 2021-10-18
EP4223311B1 (en) 2025-06-25
RS59369B1 (sr) 2019-11-29
CY1126128T1 (el) 2023-11-15
EP3892295A1 (en) 2021-10-13
EP2714071B1 (en) 2019-07-10
CY1124685T1 (el) 2022-07-22
EP3892295B1 (en) 2023-04-26
PL3473267T3 (pl) 2022-01-10
HRP20191535T1 (hr) 2019-11-29
CY1122110T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
SG11201400846PA (en) Adjustable fracturing system
IL231043A0 (en) vaccine
GB201120860D0 (en) Cancer immunotherapy
SG11201401632WA (en) Antigen presenting cancer vaccine
GB201119999D0 (en) Vaccine
ME03498B (me) Individualizovane vakcine protiv kancera
ZA201306245B (en) Combination vaccines
PL2729158T3 (pl) Szczepionki przeciwko Chlamydia
SG2014007694A (en) Radiation source
GB201120000D0 (en) Vaccine
GB201106630D0 (en) Cancer therapy
HK40098119A (en) Individualized vaccines for cancer
GB201107549D0 (en) Cancer vaccine
GB201108982D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201108984D0 (en) Vaccines
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
IL231330A0 (en) Cancer diagnosis methods
GB201118153D0 (en) Therapies for cancers
GB201116342D0 (en) Antigen combinations
GB201109294D0 (en) Novel vaccine
GB201118220D0 (en) Cancer therapy